Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Agenus stock
Learn how to easily invest in Agenus stock.
Agenus Inc is a biotechnology business based in the US. Agenus shares (AGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Agenus employs 441 staff and has a trailing 12-month revenue of around $320.1 million.
How to buy shares in Agenus
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AGEN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Agenus stock price (NASDAQ: AGEN)Use our graph to track the performance of AGEN stocks over time.
Agenus shares at a glance
|Latest market close||$2.04|
|52-week range||$1.25 - $5.94|
|50-day moving average||$2.66|
|200-day moving average||$2.49|
|Wall St. target price||$9.33|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.18|
Buy Agenus shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Agenus stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Agenus price performance over time
|1 week (2022-09-21)||-9.73%|
|1 month (2022-08-26)||-23.60%|
|3 months (2022-06-28)||10.87%|
|6 months (2022-03-25)||-24.44%|
|1 year (2021-09-28)||-60.92%|
|2 years (2020-09-28)||-49.63%|
|3 years (2019-09-27)||2.66|
|5 years (2017-09-28)||4.42|
Is Agenus stock undervalued or overvalued?
Valuing Agenus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Agenus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Agenus's P/E ratio
Agenus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Agenus shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Agenus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $57.5 million.
The EBITDA is a measure of a Agenus's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$320.1 million|
|Operating margin TTM||15.86%|
|Gross profit TTM||$113.6 million|
|Return on assets TTM||9.79%|
|Return on equity TTM||0%|
|Market capitalisation||$603.1 million|
TTM: trailing 12 months
Agenus share dividends
We're not expecting Agenus to pay a dividend over the next 12 months.
Have Agenus's shares ever split?
Agenus's shares were split on a 1:6 basis on 2 October 2011. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Agenus shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Agenus shares which in turn could have impacted Agenus's share price.
Agenus share price volatility
Over the last 12 months, Agenus's shares have ranged in value from as little as $1.25 up to $5.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agenus's is 1.1558. This would suggest that Agenus's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Agenus Inc. , a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc.
Agenus in the news
Bet on These 4 Biotech Stocks With Bright Prospects
AstraZeneca's (AZN) Ultomiris Gets EC Nod for New Indication
Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris
Frequently asked questionsWhat percentage of Agenus is owned by insiders or institutions?
Currently 9.641% of Agenus shares are held by insiders and 53.055% by institutions. How many people work for Agenus?
Latest data suggests 441 work at Agenus. When does the fiscal year end for Agenus?
Agenus's fiscal year ends in December. Where is Agenus based?
Agenus's address is: 3 Forbes Road, Lexington, MA, United States, 02421-7305 What is Agenus's ISIN number?
Agenus's international securities identification number is: US00847G7051 What is Agenus's CUSIP number?
Agenus's Committee on Uniform Securities Identification Procedures number is: 00847G101
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert